Primary study · included by 1 review
Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.
Solans 2001 · Solans R, Bosch J A, Galofré P, et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2001
Included by
| Outcome this study informs | Pooled effect | Evidence | Certainty |
|---|---|---|---|
Xerostomia (pooled prevalence) Radioiodine (I131) therapy · within 2 months after RIT | Prevalence 0.60 [0.28, 0.85] | 3 studies · 1502 participants | GRADE not reported |
Xerostomia (pooled prevalence) Radioiodine (I131) therapy · more than 1 year after RIT | Prevalence 0.17 [0.10, 0.28] | 6 studies · 1005 participants | GRADE not reported |
Xerostomia High administered I131 activity (study-specific thresholds) vs Low administered I131 activity (study-specific thresholds) | OR 7.14 [2.02, 25.26] | 3 studies | GRADE not reported |
Xerostomia (pooled prevalence) Radioiodine (I131) therapy · between 6 months and 1 year after RIT | Prevalence 0.19 [0.14, 0.25] | 5 studies · 885 participants | GRADE not reported |
Xerostomia High administered I131 activity (study-specific thresholds) vs Low administered I131 activity (study-specific thresholds) | OR 4.23 [1.04, 17.15] | 4 studies | GRADE not reported |
1 including review in total.